CCRM
Bilal B. Mughal is a seasoned scientist with extensive experience in stem cell research and contract project management, currently serving as Lead Scientist II at CCRM. In this role, Bilal leads client research projects, notably generating iPSC-derived neural cells and developing protocols for IND applications. Prior to CCRM, Bilal held postdoctoral positions at CERVO Brain Research Centre and the University of Liège, focusing on psychiatric disorders using patient-derived iPSCs and research on brain and inner ear disorders, respectively. Bilal's academic foundation includes a Ph.D. in Neuroendocrinology from Sorbonne Université, a Master's in Molecular Medicine from The University of Sheffield, and a Bachelor's in Genetics from the University of Leeds.
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.